Results

Total Results: 463 records

Showing results for "renal".

101. Management of Gout | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/gout/research-protocol
     November 03, 2014 - Hyperuricemia can be the result of either inadequate renal excretion of UA or, less commonly, UA overproduction … (XOIs- allopurinol and febuxostat) to reduce sUA production; uricosurics probenecid, which prevents renal … differ according to patient baseline demographic characteristics and co-morbid conditions (including renal … -5) Patients with comorbidities, including hypertension, Type 2 diabetes, chronic kidney disease (renal … conducted by age group; particular comorbidities, such as patients with hypertension, type 2 DM, or renal

102. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-kidney-disease-anemia-2011_research-protocol.pdf
     January 01, 2011 - According to the United States Renal Data System, 67.4 percent of patients initiating dialysis had … Prevalence and management of anemia in renal transplant recipients: a European survey. … United States Renal Data System. 2010 USRDS Annual Data Report: Vol. 2 Atlas of End-Stage Renal Disease … The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. … CMS proposes new prospective payment system for renal dialysis facilities [press release].

103. Calcineurin_Inhibitors_Protocol_FINAL_10-07-2014 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/calcineurin-inhibitor_research-protocol.pdf
     October 08, 2014 - almost 60% of all organ transplants.1 Kidney transplantation is the treatment of choice for end stage renal … Cyclosporine and tacrolimus are the most commonly used CNIs in renal transplant recipients during the … Long term renal allograft survival in the United States: a critical reappraisal. … Reduced exposure to calcineurin inhibitors in renal transplantation. … graft dysfunction'/exp OR 'renal graft dysfunction' OR (kidney OR renal) NEAR/2 (allograft* OR alograft

104. Gout-managment-protocol-141103 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/gout_research-protocol.pdf
     November 03, 2014 - Hyperuricemia can be the result of either inadequate renal excretion of UA or, less commonly, UA overproduction … XOIs- allopurinol and febuxostat) to reduce sUA production; uricosurics probenecid, which prevents renal … differ according to patient baseline demographic characteristics and co-morbid conditions (including renal … • Patients with comorbidities, including hypertension, Type 2 diabetes, chronic kidney disease (renal … conducted by age group; particular comorbidities, such as patients with hypertension, type 2 DM, or renal

105. Comparative Effectiveness Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
     January 01, 2006 - Osteoarthritis; Acute shoulder pain; Fever OA and RA: 1,500 mg 2x/day or 3,000 mg 1x/day Renal … in 2-3 doses; Extended- release, 100-200 mg/day RA: Delayed- release, 100-200 mg/day in 3- 4 Renal … impairment(CrCl >25 mL/min) max 150 mg/day; Moderate renal impairment (CrCl l<25 mL/min) max 100 … Elderly – 4.3 to 7.6 hours; Hepatic dysfunction – 1.6 to 7.6 hours; Renal impairment – 3.4 to 18.9 … : No SS difference b/t lumiracoxib and NSAIDs for renal endpoint or serious liver AEs.

106. Methods Research Report - Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/survival-quality_research.pdf
     April 01, 2013 - Mohamed et al.,40 evaluated the benefit-risk preferences of patients with renal cell carcinoma, using … Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. … Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. … " [Supplementary Concept] OR sunitinib OR sutent) AND ("Carcinoma, Renal Cell"[Mesh] OR "renal cell … Sorafenib in advanced clear-cell renal-cell carcinoma.

107. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1412.pdf
     December 01, 2014 - gout purportedly have insufficient excretion of uric acid, which could be due to genetic defects in renal … organic anion transporter involved in controlling the reabsorption of uric acid from the proximal renal … Monotherapy lesinurad resulted in more patients experiencing elevated serum creatinine levels and renal … However, better gout management could reduce hospitalizations and renal or cardiovascular complications … also provide cost offsets from treatment with lesinurad.18 One research expert noted concerns over renal

108. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0320_06-17-2009.pdf
     January 01, 2009 - associated with these diseases (i.e., bone issues, elevated urine/serum protein, anemia, fatigue, or renal … What are the day-to-day biological variables, such as renal function, that affect the utility of FLC

109. Erythropoiesis-Stimulating-Agents-Utilization Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/erythropoiesis-stimulating-agents-utilization_research.pdf
     February 01, 2011 - Chronic renal disease affects more than 26 million Americans1 and is the cause of significant morbidity … a common complication, conveys signifi- cant risk for cardiovascular disease, faster progression of renal … failure, and decreased quality of life.3 In fact, most patients with chronic renal disease become … Early Anemia Treatment With Epoetin Beta [CREATE] 7 and Correction of Hemoglobin and Outcomes in Renal … Anemia in renal disease: diagnosis and management. Blood Rev 2010;24(1):39-47. 4. Nurko S.

110. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-update_executive.pdf
     June 01, 2011 - Number 34 Effective Health Care 2 The renin system can be triggered by sympathetic stimulation, renal … used extensively for treatment of hypertension, heart failure, myocardial infarction, diabetes, and renal … There appears to be a small difference in change in diabetes control, renal function between ACEIs and … and switch rates). • Specific adverse events (including, but not limited to, weight gain, impaired renal … e Specific adverse events: These included, but were no limited to, weight gain, impaired renal function

111. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_executive.pdf
     January 01, 2006 - Harms: hypertension, congestive heart failure (CHF), edema, and impaired renal function • All NSAIDs … Evidence regarding the comparative risk of renal dysfunction for celecoxib and rofecoxib is sparse. … event (peripheral edema, hypertension, or renal dysfunction) risk from 114 randomized trials of COX- … , although there was no difference for the prepecified, primary composite renal outcome of peripheral … edema, hypertension, renal dysfunction, or arrhythmia.

112. TND-555-09-03-2013 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-555-09-03-2013.pdf
     January 01, 2013 - Completion Date: 02-13-2013 3 Control and Complications Trial (DCCT) (as measured by retinal, renal … A decrease in or prevention of diabetes-related complications (as measured by retinal, renal, cardiovascular

113. Disposition of Comments for CERs 155 156 Contast-Induced Nephropathy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/nephropathy-contrast-induced_disposition-comments.pdf
     January 07, 2016 - whether imaging was done on an urgent or elective basis, or other details such as the severity of renal … We know that CIN incidence varies dramatically based on baseline renal function, and the absence of … It is hypothesized that patients with normal or near-normal renal function "may have" a lower risk of … resulting from changes in creatinine production, tubular secretion, volue of distribution or extra-renal … Need for renal replacement therapy is addressed in all comparisons.

114. Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/vte-prophyalaxis/research
     May 29, 2013 - antiplatelet therapy; obese or underweight patients; those having obesity surgery; or with acute or chronic renal

115. Since their introduction in 20xx, DES have been shown in clinical trials to decrease TLR (… (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/coronary-stents-outcomes_research.pdf
     January 01, 2010 - with DES plus a selected group of clinically important variables including: gender, age, diabetes, renal … As expected, mortality was higher in those with diabetes, renal failure, STEMI or CHF. … This effect was somewhat less pronounced in those with a prior history of CABG and renal failure, with … Similarly, the 30-month risk of MI was lower in all patient subgroups except those with renal failure … (Figure 4c) However, no benefit was observed in patients >75 years, or with diabetes, renal failure,

116. Heart-Failure-Natriuretic-Peptide Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-failure-natriuretic-peptide_executive.pdf
     November 01, 2013 - The BNP concentration was inversely related to renal function. … Renal function: Two papers48,80 reported an inverse association between renal function and NT-proBNP … Renal function: One study assessed the effect of renal function on test performance.101 Patients were … function: One study101 examined the effect of renal function on the ability of NT-proBNP to identify … of both BNP and NT-proBNP, and to establish cutpoints in situations of reduced renal function

117. Chronic Kidney Disease Stages 1-3: Screening, Monitoring, and Treatment (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-disease-medicine_disposition-comments.pdf
     August 01, 2012 - I demanded from the owner of my medical center that I immediately be referred to a renal nutritionist … Renal Data System (USRDS) and the Behavioral Risk Factor Surveillance System (BRFSS). … Ruben Velez Renal Physicians Association In asymptomatic adults with or without recognized risk … A recent study by the Chronic Renal Insufficiency Cohort (CRIC) Study Group showed that treatment of … Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort.

118. Serum-Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/plasma-cell-dyscrasias-sflc-assay/research-protocol
     May 02, 2011 - resulting end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal … Bone marrow plasma cells ≤10% Absence of end-organ damage (bone lesions, anemia, hypercalcemia, or renal … urinary monoclonal protein Evidence of end-organ damage (bone lesions, anemia, hypercalcemia, or renal … bone marrow plasma cells ≥10% Absence of end-organ damage (bone lesions, anemia, hypercalcemia, or renal … amyloidosis Amyloid-related systemic syndrome — organ involvement by tissue amyloid deposition (renal

119. Data Points #1: Prevalence of diabetes, diabetic foot ulcer, and lower extremity amputation among Medicare beneficiaries, 2006-2008. | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/diabetes-foot-ulcer-amputation-prevalence/research
     February 17, 2011 - Those with diabetes are expected to suffer from several associated medical complications, such as renal … The prevalence of LEA in nonelderly diabetics with PAD (many of whom likely have end-stage renal disease

120. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer18-heart-disease-ace-inhibitor-arb-executive.pdf
     October 01, 2009 - presence and pattern of symptoms), dose of the ACE inhibitor or ARB used, comorbidities (diabetes, renal … Patients with renal dysfunction have at least as robust relative reductions in the risk of cardiovascular … Renal impairment Moderate • Combination of ACE inhibitor + ARB (ramipril + withdrawal telmisartan) has … more discontinuations due to renal impairment than ACE inhibitor (ramipril) alone. … Renal impairment Insufficient • No data are available evaluating ACE inhibitors or ARBs or hyperkalemia